TX-RAPID-MEDICAL/KANEKA
13.12.2023 16:04:32 CET | Business Wire | Press release
Rapid Medical™, a leading developer of advanced neurovascular devices, announced Japanese approval for its TIGERTRIEVER revascularization device. With Pharmaceuticals and Medical Devices Agency (PMDA) approval, TIGERTRIEVER serves as the first device to offer individualized solutions for mechanical thrombectomy.
TIGERTRIEVER technology is inspired by advancements in aerospace engineering and transforms thrombectomy procedures from a passive to an active approach. Compared to traditional stent retrievers, TIGERTRIEVER offers user control–this is of particular importance in Japan and other Asian countries with a high prevalence of underlying intracranial atherosclerotic disease (ICAD). The device can be expanded and reduced on demand, activating clot integration and potentially reducing the risk of vessel perforation or damage during device retrieval.
“Japan now has access to a single tool that adjusts specifically to the patient’s anatomy for high first pass success,” states Eitan Havis, President, International at Rapid Medical. “It has been a much-needed endeavor to introduce patient-specific stroke procedures to Japan and other Asian countries like China since there is no room for compromise with the brain.”
A published clinical study demonstrated superiority to conventional stent retrievers. The results of the TIGER multicenter trial presented 3 statistically significant improvements–in restoring blood flow to the brain, good clinical outcomes, and reducing emboli to new territory–compared to an average from six pivotal stent retriever trials.1 Additionally, the TIGER trial showed fast procedure times, on par with aspiration alone2, driven by a very high first-pass success rate. A subgroup analysis maintained these excellent results even in challenging stenotic ICAD patients.3
About Rapid Medical
Kaneka Corporation, headquartered in Tokyo, Japan, has exclusive distribution rights with Rapid Medical in the country. Rapid Medical expands what’s possible in neurovascular treatment by pioneering advanced interventional devices that treat ischemic and hemorrhagic stroke. Utilizing proprietary manufacturing techniques, Rapid Medical’s products are remotely adjustable and fully visible. This enables physicians to respond in real time to the anatomy and tailor the approach to every patient for better procedural outcomes. TIGERTRIEVER™ 13, 17 and 21, COMANECI™ and COLUMBUS™/DRIVEWIRE are CE marked and FDA cleared. TIGERTRIEVER XL is also CE marked. More information is available at www.rapid-medical.com.
___________________________
1 Gupta, Rishi et al. “New Class of Radially Adjustable Stentrievers for Acute Ischemic Stroke: Primary Results of the Multicenter TIGER Trial.” Stroke vol. 52,5 (2021): 1534-1544. doi:10.1161/STROKEAHA.121.034436
2 Turk, Aquilla S 3rd et al. “Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial.” Lancet (London, England) vol. 393,10175 (2019): 998-1008. doi:10.1016/S0140-6736(19)30297-1
3 Ojeda DJ, Ghannam M, Sanchez S, et al. Tigertriever in the treatment of acute ischemic stroke with underlying intracranial atherosclerotic disease [published online ahead of print, 2023 Sep 30]. J Neurointerv Surg. 2023;jnis-2023-020796. doi:10.1136/jnis-2023-020796
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231213398321/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Textron Aviation Marks 500th Cessna Citation Latitude Rollout22.9.2026 16:19:00 CEST | Press release
Milestone reinforces the Citation Latitude’s position as the world’s best-selling midsize business jet. Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced the rollout of the 500th Cessna Citation Latitude business jet from the company’s Wichita, Kansas, manufacturing facility. The production milestone highlights the continued success of the world’s best-selling midsize business jet and recognizes the employees whose craftsmanship and dedication have helped make the Citation Latitude the trusted choice for operators around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922867287/en/ Textron Aviation marks 500th Cessna Citation Latitude rollout. (Photo Credit: Textron Aviation) “The rollout of the 500th Citation Latitude is a testament to the employees who build this aircraft with dedication and pride every day,” said Eric Cardinali, senior vice president, Manufacturing. “Behind every aircr
OCP Announces Date of Second Quarter and First Half 2026 Earnings22.9.2026 16:00:00 CEST | Press release
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its second quarter and first half 2026 results on Tuesday, September 29, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 10:00 a.m. EDT, 2:00 p.m. Morocco (GMT) and 3:00 p.m. London time (GMT+1). OCP senior management will host a conference call to discuss second quarter and first half 2026 results at 11:00 a.m. EDT, 3:00 p.m. Morocco (GMT) and 4:00 p.m. London time (GMT+1) on Tuesday, September 29, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century
Quaise Energy Selected for Up to $25 Million in U.S. Department of Energy Support to Advance World's First Commercial Superhot Geothermal Power Plant22.9.2026 15:30:00 CEST | Press release
Quaise's Project Obsidian, a commercial-scale superhot Enhanced Geothermal System (EGS), selected to receive federal funding as part of $99 million DOE effort to advance geothermal energy development across the United States Supports completion of the first well triplet at Project Obsidian, targeting more than 25 megawatts of gross electric power Project team includes Pacific Northwest National Laboratory, Lawrence Berkeley National Laboratory and Oregon State University Quaise Energy, a leading developer of utility-scale superhot geothermal energy, today announced that it has been selected by the U.S. Department of Energy (DOE) for up to $25 million in funding under the Next-Generation Geothermal Field Tests and Geothermal Resource Characterization and Confirmation funding opportunity. The support brings the U.S. closer to commercializing superhot Enhanced Geothermal Systems — technology that could unlock firm, clean power from hot rock beneath virtually any geography in the country.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 202622.9.2026 15:30:00 CEST | Press release
Late-Breaking Abstract to Feature New Data from First Phase 3 Registrational Study of Arcotatug Tavatecan in Previously Treated Advanced Gastric CancerTAK-928 Presentations Reinforce Potential in Patients with Immunotherapy-Resistant Non-Small Cell Lung Cancer (NSCLC) and Previously Untreated NSCLCTakeda Continues to Progress Clinical Development of Arcotatug Tavatecan and TAK-928; New Non-Squamous NSCLC Sub-Trial Added to Global Phase 3 MarsLight-11 Study Evaluating TAK-928 vs. Docetaxel Monotherapy Takeda(TSE:4502/NYSE:TAK)announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026, in Madrid, Spain. Key data will include a late-breaking abstract on arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343*) and two presentations on TAK-928 (Innovent R&D code: IBI363*). Clinical and real-world analyses of ALUNBRIG® (brigatinib) and FRUZAQLA® (fruquintinib) will also be
From CSR to Public Health Impact: How Colgate Bright Smiles, Bright Futures® is Driving Behavior Change for the Next Billion Children and Their Families22.9.2026 15:00:00 CEST | Press release
Colgate-Palmolive builds on its legacy of oral health, publishing an impact evaluation, evolving its health education tools rooted in behavior change, and scaling its global health partnerships. Colgate-Palmolive, the worldwide leader in oral care, announced a strategic evolution in its flagship oral health education program, Colgate Bright Smiles, Bright Futures® (BSBF), reflecting the Company’s commitment to global public health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922129016/en/ Launched in 1991, the program has reached over two billion children and their families across more than 100 countries, demonstrating how private-sector commitment designed to support communities, can become a powerful force for public health, driving healthier behaviors and positive outcomes at scale. From health education curriculum and school programming to mobile dental vans and free oral health screenings, BSBF helps children and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom